Judge trims EmblemHealth's US antitrust claims against Alexion over Soliris
EmblemHealth’s US antitrust claims against Alexion Pharmaceuticals alleging unlawful delay of competition for its drug Soliris were trimmed Friday by a Massachusetts federal judge. US District Judge Brian Murphy dismissed Emblem’s...To view the full article, register now.
Already a subscriber? Click here to view full article